{"gene":"FCGRT","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":1999,"finding":"FcRn mediates bidirectional, pH-dependent, receptor-specific transcytosis of IgG across polarized human intestinal epithelial cells (T84 line), establishing a mechanism for IgG transport at mucosal surfaces in adult humans.","method":"Solute flux/transcytosis assays in polarized T84 monolayers, immunocytochemistry, endosomal acidification inhibition","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (flux assay, IHC, pharmacological inhibition) in a well-controlled polarized epithelial model","pmids":["10510331"],"is_preprint":false},{"year":1998,"finding":"FcRn is functionally expressed in endothelial cells of mice, localized within cytosolic vesicular structures, and is the site at which serum IgG homeostasis is maintained.","method":"Immunohistochemistry, immunoprecipitation, immunofluorescence of cultured murine endothelial cells, tissue distribution of FcRn-binding proteins","journal":"International immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (IHC, IP, IF) with functional localization in relevant primary cells","pmids":["9786428"],"is_preprint":false},{"year":2004,"finding":"FcRn segregates IgG-FcRn complexes from unbound IgG in sorting endosomes; FcRn-IgG complexes are depleted from sorting endosomes generating multivesicular bodies destined for lysosomal degradation, while rescued IgG is recycled. FcRn trafficking overlaps with the transferrin receptor pathway.","method":"Live cell imaging of FcRn-GFP transfected human endothelial cells, fluorescence microscopy","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — live-cell imaging with functional consequence (IgG sorting/recycling) in human endothelial cells","pmids":["14764666"],"is_preprint":false},{"year":2000,"finding":"The FcRn binding site on human IgG1 was mapped to the CH2-CH3 domain interface of the Fc region; key residues were identified that, when mutated, abrogated or enhanced binding to FcRn (and other FcγRs).","method":"Alanine-scanning mutagenesis of IgG1 Fc combined with binding assays (ELISA, SPR) for FcγRI, FcγRII, FcγRIII, and FcRn","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis with quantitative binding assays across multiple receptors, widely replicated","pmids":["11096108"],"is_preprint":false},{"year":2006,"finding":"FcRn is expressed in azurophilic and specific granules of neutrophils, relocates to phagolysosomes upon phagocytosis of IgG-opsonized bacteria, and enhances phagocytosis in a pH-dependent, IgG-recycling-independent manner; FcRn-deficient neutrophils show impaired phagocytosis.","method":"FcRn-knockout and β2M-knockout mouse neutrophils, phagocytosis assays, IgG H435A mutant (FcRn-binding-deficient), TAT-peptide inhibition of intracellular FcRn motifs","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches (KO mice, binding-deficient IgG mutant, peptide inhibitor) with clear cellular phenotype","pmids":["16849638"],"is_preprint":false},{"year":2006,"finding":"The M252Y/S254T/T256E (YTE) triple mutation in the IgG1 Fc domain increases binding to human and cynomolgus FcRn 10-fold at pH 6.0 while preserving release at pH 7.4, resulting in ~4-fold increased serum half-life and increased lung bioavailability in primates.","method":"In vitro FcRn binding assays (pH-dependent), pharmacokinetic studies in cynomolgus monkeys, ADCC assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — Fc mutagenesis with in vitro binding plus in vivo PK readout in primates; widely replicated","pmids":["16793771"],"is_preprint":false},{"year":2001,"finding":"Human placental endothelial cells express functional FcRn and mediate transcytosis of IgG preferentially from the basolateral to apical compartment; IgG and FcRn co-localize in a chloroquine-sensitive intracellular endocytic compartment.","method":"Indirect immunofluorescence, RT-PCR, 125I-IgG transcytosis assay in double-chamber system, electron microscopy with colloidal gold","journal":"Human immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (IF, RT-PCR, radiotracer transcytosis, EM) in primary human placental endothelial cells","pmids":["11182218"],"is_preprint":false},{"year":2002,"finding":"FcRn expressed in polarized MDCK cells mediates IgG transcytosis and recycling; in the absence of IgG, FcRn distributes predominantly apically, but redistributes to basolateral locations upon IgG binding—indicating ligand-induced redistribution signaling transcytosis. PI3-kinase inhibition disrupts basolateral but not apical recycling; apically internalized IgG recycles mainly from wortmannin-insensitive apical early endosomes, while transcytosing IgG passes through Rab11-positive apical recycling endosomes.","method":"Pulse-chase experiments, confocal microscopy, quantitative IgG transport assays, pharmacological inhibitors (wortmannin) in polarized MDCK cells expressing rat FcRn","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — reconstitution in polarized epithelial cells with mechanistic dissection using inhibitors and quantitative transport measurements","pmids":["11847107"],"is_preprint":false},{"year":2009,"finding":"Methionine oxidation at Met252 and Met428 in the IgG2 Fc region decreases binding affinity to both FcRn and Protein A, establishing that these solvent-exposed methionine residues at the FcRn binding interface are critical for the FcRn-IgG interaction.","method":"In vitro oxidation kinetics, binding affinity measurements (SPR/ELISA) for FcRn and Protein A","journal":"Protein science","confidence":"High","confidence_rationale":"Tier 1 — site-specific chemical modification with quantitative binding assays, mechanistically clear","pmids":["19165723"],"is_preprint":false},{"year":2015,"finding":"Two FcRn molecules bind an IgG homodimer independently and with identical affinities at the two Fc sites (KD ~760 nM at pH 5.8 for human FcRn/human IgG1); in vivo serum half-life is influenced by both affinity and avidity of FcRn-IgG interactions.","method":"Surface plasmon resonance biosensor assays (artifact-controlled), in vivo PK in mouse and rat models","journal":"mAbs","confidence":"High","confidence_rationale":"Tier 1 — rigorous SPR with artifact controls, consistent with crystallographic data, supported by in vivo PK","pmids":["25658443"],"is_preprint":false},{"year":2014,"finding":"An FcRn binding affinity threshold at neutral pH (pH 7.4) governs IgG recycling efficiency: Fc variants with acidic pH-enhanced binding but neutral-pH affinity below this threshold exhibit extended serum half-life, while those with neutral-pH affinity above the threshold show rapid clearance.","method":"Fc mutagenesis panel, SPR binding at pH 6.0 and 7.4, pharmacokinetic studies in human FcRn transgenic mice and cynomolgus monkeys","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis with pH-dependent binding assays and in vivo PK validation in two species","pmids":["25538249"],"is_preprint":false},{"year":2017,"finding":"Hepatic FcRn mediates basal recycling and bidirectional transcytosis of albumin and directs newly synthesized albumin into the basal (blood-side) milieu; liver-specific or global FcRn deletion causes hypoalbuminemia, biliary albumin loss, and intracellular albumin accumulation, and paradoxically protects from APAP-induced liver injury by increased intracellular albumin scavenging of reactive oxygen species.","method":"Global and liver-specific FcRn-knockout mice, in vitro polarized cell models, pharmacological FcRn blockade with mAbs and peptide mimetics, biochemical fractionation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — tissue-specific KO plus in vitro mechanistic models plus pharmacological intervention, multiple orthogonal readouts","pmids":["28330995"],"is_preprint":false},{"year":2017,"finding":"FcRn-driven endosomal sorting directs albumin away from lysosomes: albumin with high FcRn-binding affinity is preferentially sorted to recycling (not lysosomal) compartments, with ~3.3-fold more recycled back to the medium compared to wild-type albumin, demonstrating the FcRn-dependent endosomal salvage pathway for albumin.","method":"Flow cytometry, quantitative confocal microscopy, albumin-recycling assay using wild-type and engineered albumins with varied FcRn affinities in low- and high-FcRn-expressing endothelial cell lines","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with affinity-engineered variants and multiple orthogonal cellular assays","pmids":["28637874"],"is_preprint":false},{"year":2019,"finding":"FcRn rescues albumin and IgG from degradation by mediating their rapid recycling from early macropinosomes via SNX5-positive membrane domains and tubular carriers to the plasma membrane in primary macrophages; IgG endocytosed by macropinocytosis follows this pathway, distinct from IgG bound to surface FcγRs.","method":"Primary mouse macrophages selectively expressing human FcRn, live-cell imaging, confocal microscopy, fluorescent albumin/IgG tracking, SNX5/Rab11 marker co-localization","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 — primary cell model with human FcRn, multiple imaging methods, clear mechanistic distinction between pathways","pmids":["31444284"],"is_preprint":false},{"year":2018,"finding":"The albumin fusion protein rIX-FP is recycled by FcRn via the albumin moiety: following internalization at low pH, rIX-FP traffics into Rab11+ recycling endosomes (within 10–15 min) and is exported from the cell; an FcRn interaction-defective albumin variant localizes to lysosomes instead.","method":"Confocal microscopy, Rab11/EEA1 co-localization, FcRn-positive vs. negative cell lines, albumin variants with FcRn-defective mutations","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — mechanistic dissection with FcRn-defective variant controls and organelle markers in relevant cell lines","pmids":["29523681"],"is_preprint":false},{"year":2017,"finding":"Complementarity-determining regions (CDRs) of IgG variable domains, particularly CDR-L3, significantly alter IgG affinity for FcRn (up to 79-fold variation) and correlate with in vivo IgG clearance in human FcRn transgenic mice, beyond the canonical Fc CH2-CH3 binding interface.","method":"SPR steady-state binding assay of >50 IgG molecules with identical Fc domains but different variable regions, in vivo PK in hFcRn transgenic mice","journal":"mAbs","confidence":"High","confidence_rationale":"Tier 2 — large panel SPR with in vivo PK correlation, mechanistically establishing CDR contribution to FcRn binding","pmids":["28991504"],"is_preprint":false},{"year":2019,"finding":"Human cytomegalovirus US11 protein inhibits FcRn assembly with β2-microglobulin, retains FcRn in the ER, and recruits ubiquitin enzymes Derlin-1, TMEM129, and UbE2J2 to initiate ER-associated degradation (ERAD) of FcRn, thereby blocking FcRn trafficking to endosomes and reducing IgG transcytosis and IgG half-life.","method":"Co-immunoprecipitation, Western blot, IgG transcytosis assays in FcRn-expressing intestinal/placental epithelial and endothelial cells, HCMV infection experiments","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — mechanistic co-IP identifying specific ERAD machinery components, functional transcytosis assays","pmids":["31289263"],"is_preprint":false},{"year":2010,"finding":"Endogenous FcRn is distributed predominantly throughout the endosomal system at steady state, with only a low percentage at the plasma membrane; a fraction of cell-surface FcRn is endocytosis-resistant while the remainder undergoes rapid endocytosis and is replenished from an internal pool.","method":"Live-cell imaging, antibody feeding assays, FACS, fluorescence microscopy of cells expressing endogenous FcRn","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization experiments with functional modeling, single lab","pmids":["28817705"],"is_preprint":false},{"year":2010,"finding":"FcRn-expressing MDCK cells show that FcRn and pIgR traffic through partly overlapping endosomal compartments (EEA1+, Rab11+, transferrin-positive recycling endosomes) but with directional differences; FcRn-mediated apical-to-basolateral IgG transcytosis depends on microtubules similarly to pIgR-mediated basolateral-to-apical transport.","method":"Confocal fluorescence microscopy, pulse-chase in co-transfected MDCK cells, live-cell imaging, microtubule depolymerization","journal":"Traffic","confidence":"Medium","confidence_rationale":"Tier 2 — comparative mechanistic study in well-established model, single lab","pmids":["20525015"],"is_preprint":false},{"year":2015,"finding":"FcRn mediates transplacental transport of IgE in the form of IgG anti-IgE/IgE immune complexes (but not monomeric IgE); IgG anti-IgE/IgE complexes bind to and are transcytosed by FcRn-expressing MDCK cells in an FcRn-dependent manner.","method":"FcRn-transfected MDCK cell transcytosis assays, clinical correlation of maternal/cord blood IgG anti-IgE/IgE IC levels","journal":"Clinical and experimental allergy","confidence":"Medium","confidence_rationale":"Tier 2 — cell-based transcytosis assay with FcRn-expressing model cells plus clinical correlation","pmids":["25652137"],"is_preprint":false},{"year":2022,"finding":"The Fab region of full-length IgG impairs interaction with membrane-associated FcRn (but not soluble FcRn in cell-free assays), reducing intracellular FcRn occupancy compared to Fc-only fragments; the crystal structure of Fc-MST-HN/FcRn provides a structural explanation for why the Fab disrupts binding in the membrane context.","method":"Crystal structure determination of Fc-MST-HN/FcRn complex, cell-based FcRn binding assays, intracellular accumulation measurements, SPR (cell-free), in vivo IgG reduction in cynomolgus monkeys","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus orthogonal cell-based and in vivo assays demonstrating functional consequence","pmids":["36241613"],"is_preprint":false},{"year":2023,"finding":"IgG Fab glycosylation hinders FcRn-mediated transplacental transport (~20% reduction); in a cell membrane context (but not in cell-free SPR assays) Fab glycans negatively impact IgG-FcRn interaction and reduce transcytosis efficiency.","method":"SPR, FcRn affinity chromatography (cell-free), cell membrane-context binding assays, clinical measurement of placental transfer of Fab-glycosylated IgG","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal in vitro methods plus in vivo clinical correlation, mechanistic distinction between cell-free and membrane-context","pmids":["36480251"],"is_preprint":false},{"year":2004,"finding":"The mouse Fcgrt 5' proximal promoter contains at least two upstream regulatory regions with repressor/activator functions; transcription factors NF1, Sp1 (GT box), and Ets bind regulatory motifs; Sp1 binding to the GT box up-regulates promoter activity, while Ets binding represses it; NF1 binding differs between neonatal enterocytes and adult cells, suggesting tissue/developmental regulation of FcRn expression.","method":"Reporter gene (luciferase) assays, electrophoretic mobility shift assay (EMSA), site-directed mutagenesis of promoter elements","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — EMSA and mutagenesis establish transcription factor binding and functional effects on promoter, single lab","pmids":["15627500"],"is_preprint":false},{"year":2018,"finding":"MicroRNA hsa-miR-3181 directly binds the 3'-UTR of FCGRT and reduces FCGRT mRNA and FcRn protein expression in multiple human cell lines (A549, HEK293, HepG2), identifying it as an epigenetic regulator of FcRn.","method":"Luciferase reporter assay with FCGRT 3'-UTR, microRNA mimic/inhibitor transfection, RT-qPCR, Western blot","journal":"Pharmaceutical research","confidence":"Medium","confidence_rationale":"Tier 2 — luciferase reporter with 3'-UTR plus mRNA and protein readouts, single lab","pmids":["29302759"],"is_preprint":false},{"year":2019,"finding":"DNA methylation in the FCGRT regulatory region (−1058 to −587 bp) contributes to variable FcRn expression; CpG site methylation reduces binding of methylation-sensitive transcription factors Zbtb7a and Sp1, shown by chromatin immunoprecipitation in model cell lines.","method":"Quantitative DNA methylation analysis, luciferase reporter assays, chromatin immunoprecipitation (ChIP), RT-qPCR, human liver/myocardium tissue samples","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP plus luciferase reporter plus methylation correlation in human tissue, single lab","pmids":["31209240"],"is_preprint":false},{"year":2016,"finding":"TGEV infection of porcine intestinal epithelial cells (IPEC-J2) up-regulates FcRn expression via activation of NF-κB signaling; four NF-κB binding sites in the pFcRn promoter were functionally validated by luciferase reporter, ChIP, EMSA, and supershift assays; NF-κB inhibition with BAY 11-7082 reversed this up-regulation.","method":"Luciferase reporter assay, ChIP, EMSA, supershift assay, NF-κB inhibitor (BAY 11-7082), RT-qPCR in IPEC-J2 cells","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — multiple mechanistic methods (ChIP, EMSA, luciferase) for NF-κB regulation of pFcRn, single lab","pmids":["27555521"],"is_preprint":false},{"year":2025,"finding":"Nipocalimab (anti-FcRn antibody) binds a unique epitope on the IgG-binding site of FcRn with pH-independent high affinity; its crystal structure (Fab/FcRn complex) reveals the structural basis for pH-independent binding, distinguishing it mechanistically from other FcRn antagonists; it selectively reduces IgG without affecting other immunoglobulin classes or immune functions.","method":"Crystal structure of nipocalimab Fab/FcRn complex, cell-based FcRn occupancy assays, in vivo dose-response studies in mice and cynomolgus monkeys","journal":"mAbs","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with cell-based and in vivo functional validation","pmids":["39936406"],"is_preprint":false},{"year":2024,"finding":"Different FcRn antagonists differentially affect albumin homeostasis through two mechanisms: (1) increased degradation of FcRn itself (reducing overall FcRn-mediated recycling of albumin) and (2) direct competition between the antagonist and albumin for FcRn binding, with the relative contribution of each mechanism varying by antagonist.","method":"Cellular and molecular analyses of a panel of FcRn antagonists, FcRn degradation assays, competitive binding assays","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic cellular analyses with panel comparison, single lab","pmids":["38713534"],"is_preprint":false},{"year":2024,"finding":"FcRn-dependent IgG recycling in adipose progenitor cells and macrophages governs IgG accumulation in adipose tissue during obesity; this accumulated IgG interacts with the insulin receptor ectodomain via its Fc-CH3 domain, hindering insulin binding and impairing insulin signaling; targeting FcRn abolished IgG accumulation and corrected insulin resistance in diet-induced obesity.","method":"Diet-induced obesity mouse models, FcRn targeting in vivo, AI-assisted modeling of IgG/insulin receptor interaction, in vitro insulin signaling assays, macrophage/progenitor cell analyses","journal":"Cell metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo FcRn targeting with defined metabolic phenotype plus molecular interaction modeling, single lab, some mechanistic steps computational","pmids":["39674176"],"is_preprint":false},{"year":2005,"finding":"FcRn is expressed in normal human epidermal keratinocytes, localized in cytoplasmic vesicular/granular structures predominantly intracellularly, and binds human IgG in an Fc-dependent, pH-dependent manner (at acidic pH).","method":"RT-PCR, Northern blot, immunoblot, immunoprecipitation, immunofluorescence microscopy, FACS, IgG binding assay at acidic pH","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods establishing FcRn expression and functional IgG binding in keratinocytes, single lab","pmids":["15654966"],"is_preprint":false},{"year":1997,"finding":"FcRn is expressed on human intestinal epithelial cells (fetal and adult), localized predominantly in the apical region of enterocytes, consistent with its role in IgG binding and transport.","method":"RT-PCR, Western blot, immunohistochemistry of human fetal and adult intestinal tissue","journal":"Immunology","confidence":"Medium","confidence_rationale":"Tier 3 — localization established by immunohistochemistry and Western blot, single lab, no direct functional assay","pmids":["9370926"],"is_preprint":false},{"year":2021,"finding":"Human FcRn expression is required for Echovirus 11 (E11) pathogenesis in mice; hFcRn serves as the primary receptor for echoviruses, but hFcRn expression alone is insufficient for susceptibility—ablation of type I IFN signaling in addition to hFcRn expression recapitulates echovirus pathogenesis and liver damage observed in humans.","method":"hFcRn transgenic mice, IFNAR-knockout mice, in vivo echovirus infection, Luminex multianalyte profiling, histopathology","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis in transgenic/KO mice with clear in vivo phenotype, single lab","pmids":["33513208"],"is_preprint":false}],"current_model":"FcRn (encoded by FCGRT) is an MHC class I-related heterodimer (α-chain/β2-microglobulin) that binds IgG and albumin in a pH-dependent manner (tight at acidic endosomal pH ~6, negligible at physiological pH ~7.4) within intracellular vesicles of diverse cell types—including endothelial cells, epithelial cells, neutrophils, macrophages, hepatocytes, and keratinocytes—where it salvages both ligands from lysosomal degradation by routing them through Rab11+ recycling endosomes/SNX5+ macropinosome tubules back to the cell surface, thereby maintaining long serum half-lives of IgG and albumin; additionally, FcRn mediates bidirectional transcytosis of IgG across polarized epithelia (intestine, placenta, nasal, BBB), facilitates phagocytosis of IgG-opsonized bacteria in a pH-dependent manner in neutrophils, delivers IgG immune complexes to antigen-presentation compartments, and can be exploited or blocked therapeutically to either extend IgG half-life (via Fc engineering) or accelerate IgG catabolism (via FcRn antagonists) for treating autoimmune diseases."},"narrative":{"teleology":[{"year":1997,"claim":"Establishing that FcRn is expressed in human adult and fetal intestinal epithelium resolved the question of whether the neonatal Fc receptor, initially studied in rodents, also operates in human gut, opening the field to studying its mucosal immune function in humans.","evidence":"RT-PCR, Western blot, and immunohistochemistry of human fetal and adult intestinal tissue","pmids":["9370926"],"confidence":"Medium","gaps":["No direct functional transport assay performed","Expression levels across intestinal segments not quantified"]},{"year":1998,"claim":"Demonstrating that FcRn is expressed in endothelial cells within intracellular vesicles established that vascular endothelium—not just epithelium—is the principal site of IgG homeostatic regulation in the adult.","evidence":"Immunohistochemistry, immunoprecipitation, and immunofluorescence of murine endothelial cells","pmids":["9786428"],"confidence":"High","gaps":["Human endothelial expression not directly shown in this study","Mechanism of IgG sorting not yet addressed"]},{"year":1999,"claim":"Showing that FcRn mediates bidirectional, pH-dependent IgG transcytosis across polarized human intestinal epithelial cells established FcRn as a mucosal IgG transport receptor in humans, not merely a salvage receptor.","evidence":"Transcytosis assays in polarized T84 monolayers with endosomal acidification inhibition","pmids":["10510331"],"confidence":"High","gaps":["In vivo confirmation of bidirectional transport in human intestine not yet available","Relative contribution of apical-to-basolateral vs. basolateral-to-apical flux not quantified in vivo"]},{"year":2000,"claim":"Mapping the FcRn binding site to the IgG1 Fc CH2–CH3 domain interface via systematic alanine-scanning mutagenesis defined the molecular footprint governing FcRn-IgG interaction and enabled rational Fc engineering.","evidence":"Alanine-scanning mutagenesis of IgG1 Fc with SPR and ELISA binding assays for FcRn and other FcγRs","pmids":["11096108"],"confidence":"High","gaps":["Full structural model of the human FcRn–IgG complex not yet available at this time","Contribution of IgG variable regions not addressed"]},{"year":2002,"claim":"Reconstitution in polarized MDCK cells revealed that FcRn-mediated transcytosis involves ligand-induced receptor redistribution and routing through Rab11-positive recycling endosomes, with basolateral recycling dependent on PI3-kinase, establishing the intracellular trafficking itinerary of FcRn.","evidence":"Pulse-chase, confocal microscopy, and wortmannin inhibition in polarized MDCK cells expressing rat FcRn","pmids":["11847107"],"confidence":"High","gaps":["Human FcRn trafficking may differ from rat FcRn in this heterologous system","Identity of adaptor proteins linking FcRn to sorting machinery unknown"]},{"year":2004,"claim":"Live-cell imaging in human endothelial cells demonstrated that FcRn sorts IgG away from multivesicular bodies destined for lysosomes and into recycling tubules, providing direct visualization of the IgG salvage mechanism.","evidence":"Live-cell imaging of FcRn-GFP in human endothelial cells with fluorescent IgG tracking","pmids":["14764666"],"confidence":"High","gaps":["Molecular determinants of FcRn exit from sorting endosomes not identified","Quantitative stoichiometry of salvage vs. degradation not measured"]},{"year":2004,"claim":"Identification of Sp1, NF1, and Ets binding sites in the Fcgrt promoter with opposing regulatory activities established that FcRn expression is actively controlled at the transcriptional level with tissue- and developmental-stage-specific modulation.","evidence":"Luciferase reporter assays, EMSA, and site-directed mutagenesis of the mouse Fcgrt promoter","pmids":["15627500"],"confidence":"Medium","gaps":["Mouse promoter elements may not fully recapitulate human FCGRT regulation","In vivo relevance of each transcription factor binding site not confirmed"]},{"year":2006,"claim":"Two discoveries broadened FcRn biology beyond recycling: FcRn expression in neutrophil granules with relocation to phagolysosomes established a role in innate immunity via enhanced phagocytosis, while the YTE Fc mutation demonstrated that engineered FcRn affinity enhancement extends IgG half-life in primates, validating FcRn as a therapeutic target.","evidence":"FcRn-KO and β2M-KO neutrophil phagocytosis assays with IgG-opsonized bacteria; Fc-YTE mutagenesis with in vitro binding and in vivo PK in cynomolgus monkeys","pmids":["16849638","16793771"],"confidence":"High","gaps":["Mechanism by which FcRn enhances phagocytosis in the acidic phagolysosome not fully defined","Long-term immunological consequences of YTE-mediated extended half-life not assessed"]},{"year":2009,"claim":"Showing that oxidation of Met252 and Met428 at the Fc–FcRn interface reduces FcRn binding established that post-translational modifications of IgG can modulate FcRn-dependent serum persistence.","evidence":"In vitro methionine oxidation of IgG2 Fc followed by SPR/ELISA binding to FcRn and Protein A","pmids":["19165723"],"confidence":"High","gaps":["In vivo significance of methionine oxidation on IgG half-life not directly tested","Whether FcRn itself undergoes oxidative modifications affecting function is unknown"]},{"year":2015,"claim":"Quantitative SPR demonstrated that two FcRn molecules bind independently to both Fc sites of an IgG homodimer with identical affinity (~760 nM at pH 5.8), and that a neutral-pH affinity threshold governs whether enhanced acidic-pH binding translates to extended or shortened half-life, establishing the biophysical rules for Fc half-life engineering.","evidence":"Artifact-controlled SPR with stoichiometric analysis; Fc mutagenesis panel with PK in hFcRn transgenic mice and cynomolgus monkeys","pmids":["25658443","25538249"],"confidence":"High","gaps":["How avidity at the membrane surface modifies these solution-phase affinity rules is not fully resolved","The pH 7.4 threshold value may differ for non-IgG1 subclasses"]},{"year":2017,"claim":"Three studies converged to establish FcRn as a dual IgG/albumin homeostatic receptor: liver-specific FcRn deletion caused hypoalbuminemia and biliary albumin loss; FcRn-dependent endosomal sorting diverted albumin from lysosomes to recycling compartments with affinity-tunable efficiency; and IgG variable-domain CDRs were shown to modulate FcRn binding up to 79-fold beyond canonical Fc determinants.","evidence":"Liver-specific FcRn-KO mice with pharmacological blockade; albumin recycling assays with affinity-engineered variants in endothelial cells; SPR panel of >50 IgGs with identical Fc domains and PK in hFcRn transgenic mice","pmids":["28330995","28637874","28991504"],"confidence":"High","gaps":["Structural basis for CDR-mediated modulation of FcRn binding not determined","Relative contribution of hepatic vs. endothelial FcRn to systemic albumin homeostasis not quantified"]},{"year":2018,"claim":"Tracking albumin fusion proteins through Rab11+ recycling endosomes confirmed the FcRn-dependent endosomal salvage route operates for albumin-conjugated therapeutics, while miR-3181 was identified as a post-transcriptional repressor of FCGRT expression.","evidence":"Confocal microscopy with Rab11/EEA1 markers and FcRn-defective albumin variants; luciferase 3′-UTR reporter assay with miR-3181 mimic/inhibitor in multiple cell lines","pmids":["29523681","29302759"],"confidence":"High","gaps":["In vivo relevance of miR-3181 regulation of FcRn not demonstrated","Whether other miRNAs coordinately regulate FCGRT is unknown"]},{"year":2019,"claim":"Three findings expanded FcRn biology: in macrophages, FcRn rescues IgG and albumin via SNX5-positive macropinosome tubules distinct from FcγR-mediated uptake; HCMV US11 protein targets FcRn for ER-associated degradation via Derlin-1/TMEM129/UbE2J2 to evade antibody-mediated immunity; and DNA methylation of CpG sites in the FCGRT promoter modulates Zbtb7a/Sp1 binding and FcRn expression levels.","evidence":"Live-cell imaging in primary macrophages with SNX5/Rab11 markers; co-IP identifying ERAD components with transcytosis assays during HCMV infection; ChIP, luciferase reporters, and methylation analysis in cell lines and human tissues","pmids":["31444284","31289263","31209240"],"confidence":"High","gaps":["Whether other herpesviruses employ analogous FcRn evasion strategies is unknown","Functional significance of SNX5 vs. Rab11 route selectivity not defined"]},{"year":2021,"claim":"Demonstrating that human FcRn serves as the primary entry receptor for Echovirus 11 in transgenic mice—with pathogenesis requiring concomitant loss of type I IFN signaling—established FcRn as a dual-use receptor exploited by enteroviruses.","evidence":"hFcRn transgenic and IFNAR-KO mice infected with echovirus, with Luminex profiling and histopathology","pmids":["33513208"],"confidence":"Medium","gaps":["Structural basis of echovirus–FcRn interaction not resolved","Whether FcRn-mediated transcytosis facilitates viral dissemination not directly tested"]},{"year":2022,"claim":"Crystal structure of an engineered Fc/FcRn complex revealed that the IgG Fab domain sterically impairs FcRn interaction in a membrane context, explaining why Fc-only fragments occupy FcRn more efficiently than full-length IgG—informing FcRn antagonist design.","evidence":"X-ray crystallography of Fc-MST-HN/FcRn complex with cell-based FcRn occupancy assays and in vivo IgG reduction in cynomolgus monkeys","pmids":["36241613"],"confidence":"High","gaps":["Full-length IgG/FcRn co-structure on membrane not yet available","How Fab glycosylation synergizes with steric hindrance mechanistically is unclear"]},{"year":2024,"claim":"Two studies connected FcRn to metabolic disease and therapeutic mechanism: FcRn-dependent IgG recycling in adipose progenitor cells and macrophages drives obesity-associated IgG accumulation that impairs insulin receptor signaling, while different FcRn antagonists were shown to reduce albumin levels through distinct mechanisms—FcRn degradation versus direct competition for albumin binding.","evidence":"Diet-induced obesity mouse models with FcRn targeting and insulin signaling assays; cellular panel comparison of FcRn antagonists with degradation and competitive binding assays","pmids":["39674176","38713534"],"confidence":"Medium","gaps":["AI-assisted modeling of IgG–insulin receptor interaction awaits experimental structural validation","Clinical translation of FcRn targeting for insulin resistance not tested","Relative importance of FcRn degradation vs. competition for albumin binding in patients not determined"]},{"year":2025,"claim":"The crystal structure of nipocalimab Fab bound to FcRn defined a unique pH-independent epitope on the IgG-binding site, explaining how this antagonist selectively blocks IgG recycling without affecting other immunoglobulin classes, providing a structural framework for selective FcRn antagonism.","evidence":"Crystal structure of nipocalimab Fab/FcRn complex with cell-based FcRn occupancy and in vivo dose-response in mice and monkeys","pmids":["39936406"],"confidence":"High","gaps":["Long-term effects of sustained pH-independent FcRn blockade on albumin levels not fully characterized","Whether epitope differences among FcRn antagonists produce distinct clinical efficacy profiles is unknown"]},{"year":null,"claim":"Key unresolved questions include the structural basis of simultaneous IgG and albumin co-binding and sorting on the same FcRn molecule, the identity of adaptor proteins linking FcRn cytoplasmic tail to endosomal sorting machinery, and the quantitative contribution of FcRn in specific tissues (e.g., liver vs. endothelium vs. hematopoietic cells) to systemic IgG and albumin homeostasis.","evidence":"","pmids":[],"confidence":"Low","gaps":["No full-length IgG/albumin/FcRn co-structure on membranes","Adaptor proteins for FcRn cytoplasmic tail sorting signals not identified","Tissue-specific conditional knockout studies with quantitative PK modeling incomplete"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[0,2,7,12,14]},{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[0,6,7,11]}],"localization":[{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[1,2,7,13,17]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[1,2,14,29]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[17]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[16]}],"pathway":[{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[0,2,6,7,11,13,14]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,19,31]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[2,12,16]}],"complexes":["FcRn–β2-microglobulin heterodimer"],"partners":["B2M","SNX5","RAB11"],"other_free_text":[]},"mechanistic_narrative":"FcRn (encoded by FCGRT) is an MHC class I-related α-chain that heterodimerizes with β2-microglobulin and functions as the principal pH-dependent receptor for IgG and albumin homeostasis, mucosal immunity, and transplacental IgG transfer. FcRn binds IgG at the CH2–CH3 domain interface and albumin at acidic endosomal pH (~6.0) while releasing both ligands at neutral pH (~7.4), thereby diverting them from lysosomal degradation into Rab11-positive recycling endosomes and SNX5-positive tubular carriers for return to the cell surface [PMID:14764666, PMID:11847107, PMID:31444284, PMID:28637874]. In polarized epithelia and endothelia—including intestinal, placental, and endothelial cells—FcRn additionally mediates bidirectional transcytosis of IgG, with transcytosis directionality regulated by ligand-induced receptor redistribution and dependent on microtubules and PI3-kinase signaling [PMID:10510331, PMID:11182218, PMID:20525015]. Beyond IgG/albumin salvage, FcRn enhances neutrophil phagocytosis of IgG-opsonized bacteria in a pH-dependent manner, serves as a primary receptor for echovirus entry, and its hepatic expression directs polarized albumin secretion and recycling; FcRn is subject to transcriptional regulation by NF-κB, Sp1, Zbtb7a, and post-transcriptional regulation by miR-3181, and is targeted for ER-associated degradation by the HCMV immune evasin US11 [PMID:16849638, PMID:33513208, PMID:28330995, PMID:31209240, PMID:29302759, PMID:31289263]."},"prefetch_data":{"uniprot":{"accession":"P55899","full_name":"IgG receptor FcRn large subunit p51","aliases":["IgG Fc fragment receptor transporter alpha chain","Neonatal Fc receptor"],"length_aa":365,"mass_kda":39.7,"function":"Cell surface receptor that transfers passive humoral immunity from the mother to the newborn. Binds to the Fc region of monomeric immunoglobulin gamma and mediates its selective uptake from milk (PubMed:10933786, PubMed:7964511). IgG in the milk is bound at the apical surface of the intestinal epithelium. The resultant FcRn-IgG complexes are transcytosed across the intestinal epithelium and IgG is released from FcRn into blood or tissue fluids. Throughout life, contributes to effective humoral immunity by recycling IgG and extending its half-life in the circulation. Mechanistically, monomeric IgG binding to FcRn in acidic endosomes of endothelial and hematopoietic cells recycles IgG to the cell surface where it is released into the circulation (PubMed:10998088). In addition of IgG, regulates homeostasis of the other most abundant circulating protein albumin/ALB (PubMed:24469444, PubMed:28330995) (Microbial infection) Acts as an uncoating receptor for a panel of echoviruses including Echovirus 5, 6, 7, 9, 11, 13, 25 and 29","subcellular_location":"Cell membrane; Endosome membrane","url":"https://www.uniprot.org/uniprotkb/P55899/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FCGRT","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FCGRT","total_profiled":1310},"omim":[{"mim_id":"605377","title":"DYSTROPHIA MYOTONICA PROTEIN KINASE; DMPK","url":"https://www.omim.org/entry/605377"},{"mim_id":"601437","title":"Fc FRAGMENT OF IgG RECEPTOR AND TRANSPORTER; FCGRT","url":"https://www.omim.org/entry/601437"},{"mim_id":"241600","title":"IMMUNODEFICIENCY 43; IMD43","url":"https://www.omim.org/entry/241600"},{"mim_id":"160900","title":"MYOTONIC DYSTROPHY 1; DM1","url":"https://www.omim.org/entry/160900"},{"mim_id":"109700","title":"BETA-2-MICROGLOBULIN; B2M","url":"https://www.omim.org/entry/109700"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/FCGRT"},"hgnc":{"alias_symbol":["FcgammaRn","FcRn"],"prev_symbol":[]},"alphafold":{"accession":"P55899","domains":[{"cath_id":"3.30.500.10","chopping":"28-197","consensus_level":"high","plddt":95.2728,"start":28,"end":197},{"cath_id":"2.60.40.10","chopping":"203-288","consensus_level":"high","plddt":95.8388,"start":203,"end":288}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P55899","model_url":"https://alphafold.ebi.ac.uk/files/AF-P55899-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P55899-F1-predicted_aligned_error_v6.png","plddt_mean":85.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FCGRT","jax_strain_url":"https://www.jax.org/strain/search?query=FCGRT"},"sequence":{"accession":"P55899","fasta_url":"https://rest.uniprot.org/uniprotkb/P55899.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P55899/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P55899"}},"corpus_meta":[{"pmid":"17703228","id":"PMC_17703228","title":"FcRn: the neonatal Fc receptor comes of age.","date":"2007","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17703228","citation_count":1779,"is_preprint":false},{"pmid":"11096108","id":"PMC_11096108","title":"High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11096108","citation_count":920,"is_preprint":false},{"pmid":"16793771","id":"PMC_16793771","title":"Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16793771","citation_count":508,"is_preprint":false},{"pmid":"10837074","id":"PMC_10837074","title":"Multiple roles for the major histocompatibility complex class I- related receptor FcRn.","date":"2000","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10837074","citation_count":358,"is_preprint":false},{"pmid":"10510331","id":"PMC_10510331","title":"Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line.","date":"1999","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/10510331","citation_count":330,"is_preprint":false},{"pmid":"31354709","id":"PMC_31354709","title":"The Neonatal Fc Receptor (FcRn): A Misnomer?","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31354709","citation_count":325,"is_preprint":false},{"pmid":"9370926","id":"PMC_9370926","title":"Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells.","date":"1997","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9370926","citation_count":248,"is_preprint":false},{"pmid":"14764666","id":"PMC_14764666","title":"Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/14764666","citation_count":245,"is_preprint":false},{"pmid":"25674083","id":"PMC_25674083","title":"Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics.","date":"2015","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25674083","citation_count":244,"is_preprint":false},{"pmid":"31118245","id":"PMC_31118245","title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.","date":"2019","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31118245","citation_count":216,"is_preprint":false},{"pmid":"24156398","id":"PMC_24156398","title":"Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics.","date":"2013","source":"Critical reviews in biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/24156398","citation_count":201,"is_preprint":false},{"pmid":"9786428","id":"PMC_9786428","title":"Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice.","date":"1998","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9786428","citation_count":201,"is_preprint":false},{"pmid":"25703189","id":"PMC_25703189","title":"The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.","date":"2015","source":"Advanced drug delivery reviews","url":"https://pubmed.ncbi.nlm.nih.gov/25703189","citation_count":181,"is_preprint":false},{"pmid":"9425738","id":"PMC_9425738","title":"FcRn: the MHC class I-related receptor that is more than an IgG transporter.","date":"1997","source":"Immunology today","url":"https://pubmed.ncbi.nlm.nih.gov/9425738","citation_count":165,"is_preprint":false},{"pmid":"19165723","id":"PMC_19165723","title":"Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn.","date":"2009","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/19165723","citation_count":159,"is_preprint":false},{"pmid":"25658443","id":"PMC_25658443","title":"The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.","date":"2015","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/25658443","citation_count":158,"is_preprint":false},{"pmid":"16731041","id":"PMC_16731041","title":"Perspective-- FcRn transports albumin: relevance to immunology and medicine.","date":"2006","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16731041","citation_count":157,"is_preprint":false},{"pmid":"29163461","id":"PMC_29163461","title":"Factors Affecting the FcRn-Mediated Transplacental Transfer of Antibodies and Implications for Vaccination in Pregnancy.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29163461","citation_count":146,"is_preprint":false},{"pmid":"11182218","id":"PMC_11182218","title":"Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells.","date":"2001","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11182218","citation_count":145,"is_preprint":false},{"pmid":"31821591","id":"PMC_31821591","title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.","date":"2019","source":"American journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/31821591","citation_count":144,"is_preprint":false},{"pmid":"16849638","id":"PMC_16849638","title":"FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16849638","citation_count":142,"is_preprint":false},{"pmid":"28402755","id":"PMC_28402755","title":"Distribution of FcRn Across Species and Tissues.","date":"2017","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/28402755","citation_count":138,"is_preprint":false},{"pmid":"30402880","id":"PMC_30402880","title":"M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study.","date":"2018","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/30402880","citation_count":118,"is_preprint":false},{"pmid":"19755184","id":"PMC_19755184","title":"Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn.","date":"2009","source":"Advances in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19755184","citation_count":111,"is_preprint":false},{"pmid":"30130439","id":"PMC_30130439","title":"Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.","date":"2018","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/30130439","citation_count":103,"is_preprint":false},{"pmid":"25221553","id":"PMC_25221553","title":"The Role of FcRn in Antigen Presentation.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25221553","citation_count":102,"is_preprint":false},{"pmid":"31897428","id":"PMC_31897428","title":"Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses.","date":"2019","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/31897428","citation_count":101,"is_preprint":false},{"pmid":"32896308","id":"PMC_32896308","title":"Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations.","date":"2020","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32896308","citation_count":99,"is_preprint":false},{"pmid":"19495758","id":"PMC_19495758","title":"Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn.","date":"2009","source":"Seminars in immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/19495758","citation_count":99,"is_preprint":false},{"pmid":"30143244","id":"PMC_30143244","title":"Targeting FcRn to Generate Antibody-Based Therapeutics.","date":"2018","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30143244","citation_count":94,"is_preprint":false},{"pmid":"19636712","id":"PMC_19636712","title":"Investigation of the influence of FcRn on the distribution of IgG to the brain.","date":"2009","source":"The AAPS journal","url":"https://pubmed.ncbi.nlm.nih.gov/19636712","citation_count":94,"is_preprint":false},{"pmid":"27232760","id":"PMC_27232760","title":"Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.","date":"2016","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/27232760","citation_count":89,"is_preprint":false},{"pmid":"33717213","id":"PMC_33717213","title":"The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors.","date":"2021","source":"Therapeutic advances in neurological disorders","url":"https://pubmed.ncbi.nlm.nih.gov/33717213","citation_count":86,"is_preprint":false},{"pmid":"28330995","id":"PMC_28330995","title":"Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28330995","citation_count":83,"is_preprint":false},{"pmid":"25538249","id":"PMC_25538249","title":"pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25538249","citation_count":82,"is_preprint":false},{"pmid":"26497526","id":"PMC_26497526","title":"The multiple facets of FcRn in immunity.","date":"2015","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/26497526","citation_count":81,"is_preprint":false},{"pmid":"35757719","id":"PMC_35757719","title":"Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35757719","citation_count":75,"is_preprint":false},{"pmid":"25116104","id":"PMC_25116104","title":"FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions.","date":"2014","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25116104","citation_count":74,"is_preprint":false},{"pmid":"28637874","id":"PMC_28637874","title":"Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28637874","citation_count":67,"is_preprint":false},{"pmid":"28991504","id":"PMC_28991504","title":"Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.","date":"2017","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/28991504","citation_count":64,"is_preprint":false},{"pmid":"12586485","id":"PMC_12586485","title":"Sequence and expression of the FcRn in the porcine mammary gland.","date":"2003","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/12586485","citation_count":61,"is_preprint":false},{"pmid":"36751773","id":"PMC_36751773","title":"FcRn inhibitors: a novel option for the treatment of myasthenia gravis.","date":"2023","source":"Neural regeneration research","url":"https://pubmed.ncbi.nlm.nih.gov/36751773","citation_count":60,"is_preprint":false},{"pmid":"23751752","id":"PMC_23751752","title":"Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies.","date":"2013","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/23751752","citation_count":55,"is_preprint":false},{"pmid":"25652137","id":"PMC_25652137","title":"Evidence that FcRn mediates the transplacental passage of maternal IgE in the form of IgG anti-IgE/IgE immune complexes.","date":"2015","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25652137","citation_count":54,"is_preprint":false},{"pmid":"30653981","id":"PMC_30653981","title":"KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs.","date":"2019","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/30653981","citation_count":54,"is_preprint":false},{"pmid":"33686177","id":"PMC_33686177","title":"Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity.","date":"2021","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/33686177","citation_count":51,"is_preprint":false},{"pmid":"37390454","id":"PMC_37390454","title":"Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease.","date":"2023","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37390454","citation_count":49,"is_preprint":false},{"pmid":"24404896","id":"PMC_24404896","title":"Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.","date":"2014","source":"Journal of drug targeting","url":"https://pubmed.ncbi.nlm.nih.gov/24404896","citation_count":48,"is_preprint":false},{"pmid":"29855134","id":"PMC_29855134","title":"Engineered Multifunctional Albumin-Decorated Porous Silicon Nanoparticles for FcRn Translocation of Insulin.","date":"2018","source":"Small (Weinheim an der Bergstrasse, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/29855134","citation_count":46,"is_preprint":false},{"pmid":"34563918","id":"PMC_34563918","title":"IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis.","date":"2021","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34563918","citation_count":43,"is_preprint":false},{"pmid":"36241613","id":"PMC_36241613","title":"The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36241613","citation_count":43,"is_preprint":false},{"pmid":"28817705","id":"PMC_28817705","title":"Cell surface dynamics and cellular distribution of endogenous FcRn.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28817705","citation_count":42,"is_preprint":false},{"pmid":"12514749","id":"PMC_12514749","title":"Association of bovine neonatal Fc receptor alpha-chain gene (FCGRT) haplotypes with serum IgG concentration in newborn calves.","date":"2002","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/12514749","citation_count":39,"is_preprint":false},{"pmid":"15654966","id":"PMC_15654966","title":"Expression of FcRn, the MHC class I-related receptor for IgG, in human keratinocytes.","date":"2005","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15654966","citation_count":39,"is_preprint":false},{"pmid":"33802650","id":"PMC_33802650","title":"In Translation: FcRn across the Therapeutic Spectrum.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33802650","citation_count":37,"is_preprint":false},{"pmid":"8646894","id":"PMC_8646894","title":"The human gene encoding the heavy chain of the major histocompatibility complex class I-like Fc receptor (FCGRT) maps to 19q13.3.","date":"1996","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8646894","citation_count":37,"is_preprint":false},{"pmid":"31444284","id":"PMC_31444284","title":"FcRn mediates fast recycling of endocytosed albumin and IgG from early macropinosomes in primary macrophages.","date":"2019","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/31444284","citation_count":37,"is_preprint":false},{"pmid":"9191140","id":"PMC_9191140","title":"New functions of the MHC class I-related Fc receptor, FcRn.","date":"1997","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/9191140","citation_count":36,"is_preprint":false},{"pmid":"31289263","id":"PMC_31289263","title":"Human cytomegalovirus evades antibody-mediated immunity through endoplasmic reticulum-associated degradation of the FcRn receptor.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31289263","citation_count":35,"is_preprint":false},{"pmid":"22453095","id":"PMC_22453095","title":"Monoclonal antibodies directed against human FcRn and their applications.","date":"2012","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/22453095","citation_count":35,"is_preprint":false},{"pmid":"22001393","id":"PMC_22001393","title":"The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22001393","citation_count":32,"is_preprint":false},{"pmid":"27555521","id":"PMC_27555521","title":"TGEV infection up-regulates FcRn expression via activation of NF-κB signaling.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27555521","citation_count":30,"is_preprint":false},{"pmid":"20627700","id":"PMC_20627700","title":"Association of FcRn expression with lung abnormalities and IVIG catabolism in patients with common variable immunodeficiency.","date":"2010","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/20627700","citation_count":30,"is_preprint":false},{"pmid":"36036539","id":"PMC_36036539","title":"Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis.","date":"2022","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/36036539","citation_count":30,"is_preprint":false},{"pmid":"27012525","id":"PMC_27012525","title":"Quantitative Analysis of Human Neonatal Fc Receptor (FcRn) Tissue Expression in Transgenic Mice by Online Peptide Immuno-Affinity LC-HRMS.","date":"2016","source":"Analytical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27012525","citation_count":30,"is_preprint":false},{"pmid":"34245786","id":"PMC_34245786","title":"FcRn expression in cancer: Mechanistic basis and therapeutic opportunities.","date":"2021","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/34245786","citation_count":28,"is_preprint":false},{"pmid":"32368865","id":"PMC_32368865","title":"The neonatal Fc receptor in cancer FcRn in cancer.","date":"2020","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32368865","citation_count":27,"is_preprint":false},{"pmid":"30326650","id":"PMC_30326650","title":"FcRn Expression in Wildtype Mice, Transgenic Mice, and in Human Tissues.","date":"2018","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/30326650","citation_count":27,"is_preprint":false},{"pmid":"20525015","id":"PMC_20525015","title":"Comparison of FcRn- and pIgR-mediated transport in MDCK cells by fluorescence confocal microscopy.","date":"2010","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/20525015","citation_count":27,"is_preprint":false},{"pmid":"33552238","id":"PMC_33552238","title":"VNTR2/VNTR3 genotype in the FCGRT gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis.","date":"2021","source":"Therapeutic advances in neurological disorders","url":"https://pubmed.ncbi.nlm.nih.gov/33552238","citation_count":26,"is_preprint":false},{"pmid":"20848168","id":"PMC_20848168","title":"Clinical ramifications of the MHC family Fc receptor FcRn.","date":"2010","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20848168","citation_count":26,"is_preprint":false},{"pmid":"29523681","id":"PMC_29523681","title":"Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29523681","citation_count":26,"is_preprint":false},{"pmid":"37602255","id":"PMC_37602255","title":"FcRN receptor antagonists in the management of myasthenia gravis.","date":"2023","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/37602255","citation_count":25,"is_preprint":false},{"pmid":"30323819","id":"PMC_30323819","title":"Lack of FcRn Impairs Natural Killer Cell Development and Functions in the Tumor Microenvironment.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30323819","citation_count":25,"is_preprint":false},{"pmid":"26718855","id":"PMC_26718855","title":"Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization.","date":"2015","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/26718855","citation_count":25,"is_preprint":false},{"pmid":"26634928","id":"PMC_26634928","title":"Localization of the human neonatal Fc receptor (FcRn) in human nasal epithelium.","date":"2015","source":"Protoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/26634928","citation_count":25,"is_preprint":false},{"pmid":"25024401","id":"PMC_25024401","title":"Application of FcRn binding assays to guide mAb development.","date":"2014","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/25024401","citation_count":24,"is_preprint":false},{"pmid":"11847107","id":"PMC_11847107","title":"IgG transcytosis and recycling by FcRn expressed in MDCK cells reveals ligand-induced redistribution.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11847107","citation_count":24,"is_preprint":false},{"pmid":"33513208","id":"PMC_33513208","title":"Human FcRn expression and Type I Interferon signaling control Echovirus 11 pathogenesis in mice.","date":"2021","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/33513208","citation_count":23,"is_preprint":false},{"pmid":"39674176","id":"PMC_39674176","title":"FcRn-dependent IgG accumulation in adipose tissue unmasks obesity pathophysiology.","date":"2024","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/39674176","citation_count":22,"is_preprint":false},{"pmid":"38431900","id":"PMC_38431900","title":"The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis.","date":"2024","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38431900","citation_count":22,"is_preprint":false},{"pmid":"38644454","id":"PMC_38644454","title":"Efgartigimod as a novel FcRn inhibitor for autoimmune disease.","date":"2024","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/38644454","citation_count":21,"is_preprint":false},{"pmid":"20930418","id":"PMC_20930418","title":"Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis.","date":"2010","source":"Drug metabolism and pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/20930418","citation_count":21,"is_preprint":false},{"pmid":"37932271","id":"PMC_37932271","title":"An FcRn-targeted mucosal vaccine against SARS-CoV-2 infection and transmission.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37932271","citation_count":20,"is_preprint":false},{"pmid":"38713534","id":"PMC_38713534","title":"Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin.","date":"2024","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/38713534","citation_count":20,"is_preprint":false},{"pmid":"37375507","id":"PMC_37375507","title":"Roles of FcRn in Antigen-Presenting Cells during Autoimmunity and a Clinical Evaluation of Efgartigimod as an FcRn Blocker.","date":"2023","source":"Pathogens (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/37375507","citation_count":20,"is_preprint":false},{"pmid":"36417823","id":"PMC_36417823","title":"Targeted inhibition of FcRn reduces NET formation to ameliorate experimental ulcerative colitis by accelerating ANCA clearance.","date":"2022","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36417823","citation_count":20,"is_preprint":false},{"pmid":"37381177","id":"PMC_37381177","title":"Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier.","date":"2023","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/37381177","citation_count":20,"is_preprint":false},{"pmid":"38724842","id":"PMC_38724842","title":"FcRn Inhibitor Therapies in Neurologic Diseases.","date":"2024","source":"CNS drugs","url":"https://pubmed.ncbi.nlm.nih.gov/38724842","citation_count":19,"is_preprint":false},{"pmid":"15627500","id":"PMC_15627500","title":"Functional analysis of the mouse Fcgrt 5' proximal promoter.","date":"2004","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/15627500","citation_count":19,"is_preprint":false},{"pmid":"33887405","id":"PMC_33887405","title":"Prevention of diabetes-associated fibrosis: Strategies in FcRn-targeted nanosystems for oral drug delivery.","date":"2021","source":"Advanced drug delivery reviews","url":"https://pubmed.ncbi.nlm.nih.gov/33887405","citation_count":19,"is_preprint":false},{"pmid":"39936406","id":"PMC_39936406","title":"Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties.","date":"2025","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/39936406","citation_count":18,"is_preprint":false},{"pmid":"27881707","id":"PMC_27881707","title":"A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27881707","citation_count":18,"is_preprint":false},{"pmid":"37867088","id":"PMC_37867088","title":"Therapeutic Plasma Exchange Versus FcRn Inhibition in Autoimmune Disease.","date":"2023","source":"Transfusion medicine reviews","url":"https://pubmed.ncbi.nlm.nih.gov/37867088","citation_count":18,"is_preprint":false},{"pmid":"31209240","id":"PMC_31209240","title":"Contribution of DNA methylation to the expression of FCGRT in human liver and myocardium.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31209240","citation_count":18,"is_preprint":false},{"pmid":"31975370","id":"PMC_31975370","title":"Treatment with anti-neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice.","date":"2020","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31975370","citation_count":18,"is_preprint":false},{"pmid":"39798960","id":"PMC_39798960","title":"C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis.","date":"2025","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/39798960","citation_count":17,"is_preprint":false},{"pmid":"36480251","id":"PMC_36480251","title":"IgG Fab Glycans Hinder FcRn-Mediated Placental Transport.","date":"2023","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/36480251","citation_count":17,"is_preprint":false},{"pmid":"35080749","id":"PMC_35080749","title":"Colostrogenesis: Role and Mechanism of the Bovine Fc Receptor of the Neonate (FcRn).","date":"2022","source":"Journal of mammary gland biology and neoplasia","url":"https://pubmed.ncbi.nlm.nih.gov/35080749","citation_count":17,"is_preprint":false},{"pmid":"29302759","id":"PMC_29302759","title":"Regulation of the Human Fc-Neonatal Receptor alpha-Chain Gene FCGRT by MicroRNA-3181.","date":"2018","source":"Pharmaceutical research","url":"https://pubmed.ncbi.nlm.nih.gov/29302759","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45849,"output_tokens":7669,"usd":0.126291},"stage2":{"model":"claude-opus-4-6","input_tokens":11438,"output_tokens":4669,"usd":0.260873},"total_usd":0.387164,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"FcRn mediates bidirectional, pH-dependent, receptor-specific transcytosis of IgG across polarized human intestinal epithelial cells (T84 line), establishing a mechanism for IgG transport at mucosal surfaces in adult humans.\",\n      \"method\": \"Solute flux/transcytosis assays in polarized T84 monolayers, immunocytochemistry, endosomal acidification inhibition\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (flux assay, IHC, pharmacological inhibition) in a well-controlled polarized epithelial model\",\n      \"pmids\": [\"10510331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"FcRn is functionally expressed in endothelial cells of mice, localized within cytosolic vesicular structures, and is the site at which serum IgG homeostasis is maintained.\",\n      \"method\": \"Immunohistochemistry, immunoprecipitation, immunofluorescence of cultured murine endothelial cells, tissue distribution of FcRn-binding proteins\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (IHC, IP, IF) with functional localization in relevant primary cells\",\n      \"pmids\": [\"9786428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"FcRn segregates IgG-FcRn complexes from unbound IgG in sorting endosomes; FcRn-IgG complexes are depleted from sorting endosomes generating multivesicular bodies destined for lysosomal degradation, while rescued IgG is recycled. FcRn trafficking overlaps with the transferrin receptor pathway.\",\n      \"method\": \"Live cell imaging of FcRn-GFP transfected human endothelial cells, fluorescence microscopy\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — live-cell imaging with functional consequence (IgG sorting/recycling) in human endothelial cells\",\n      \"pmids\": [\"14764666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The FcRn binding site on human IgG1 was mapped to the CH2-CH3 domain interface of the Fc region; key residues were identified that, when mutated, abrogated or enhanced binding to FcRn (and other FcγRs).\",\n      \"method\": \"Alanine-scanning mutagenesis of IgG1 Fc combined with binding assays (ELISA, SPR) for FcγRI, FcγRII, FcγRIII, and FcRn\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with quantitative binding assays across multiple receptors, widely replicated\",\n      \"pmids\": [\"11096108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"FcRn is expressed in azurophilic and specific granules of neutrophils, relocates to phagolysosomes upon phagocytosis of IgG-opsonized bacteria, and enhances phagocytosis in a pH-dependent, IgG-recycling-independent manner; FcRn-deficient neutrophils show impaired phagocytosis.\",\n      \"method\": \"FcRn-knockout and β2M-knockout mouse neutrophils, phagocytosis assays, IgG H435A mutant (FcRn-binding-deficient), TAT-peptide inhibition of intracellular FcRn motifs\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches (KO mice, binding-deficient IgG mutant, peptide inhibitor) with clear cellular phenotype\",\n      \"pmids\": [\"16849638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The M252Y/S254T/T256E (YTE) triple mutation in the IgG1 Fc domain increases binding to human and cynomolgus FcRn 10-fold at pH 6.0 while preserving release at pH 7.4, resulting in ~4-fold increased serum half-life and increased lung bioavailability in primates.\",\n      \"method\": \"In vitro FcRn binding assays (pH-dependent), pharmacokinetic studies in cynomolgus monkeys, ADCC assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — Fc mutagenesis with in vitro binding plus in vivo PK readout in primates; widely replicated\",\n      \"pmids\": [\"16793771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Human placental endothelial cells express functional FcRn and mediate transcytosis of IgG preferentially from the basolateral to apical compartment; IgG and FcRn co-localize in a chloroquine-sensitive intracellular endocytic compartment.\",\n      \"method\": \"Indirect immunofluorescence, RT-PCR, 125I-IgG transcytosis assay in double-chamber system, electron microscopy with colloidal gold\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (IF, RT-PCR, radiotracer transcytosis, EM) in primary human placental endothelial cells\",\n      \"pmids\": [\"11182218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"FcRn expressed in polarized MDCK cells mediates IgG transcytosis and recycling; in the absence of IgG, FcRn distributes predominantly apically, but redistributes to basolateral locations upon IgG binding—indicating ligand-induced redistribution signaling transcytosis. PI3-kinase inhibition disrupts basolateral but not apical recycling; apically internalized IgG recycles mainly from wortmannin-insensitive apical early endosomes, while transcytosing IgG passes through Rab11-positive apical recycling endosomes.\",\n      \"method\": \"Pulse-chase experiments, confocal microscopy, quantitative IgG transport assays, pharmacological inhibitors (wortmannin) in polarized MDCK cells expressing rat FcRn\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution in polarized epithelial cells with mechanistic dissection using inhibitors and quantitative transport measurements\",\n      \"pmids\": [\"11847107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Methionine oxidation at Met252 and Met428 in the IgG2 Fc region decreases binding affinity to both FcRn and Protein A, establishing that these solvent-exposed methionine residues at the FcRn binding interface are critical for the FcRn-IgG interaction.\",\n      \"method\": \"In vitro oxidation kinetics, binding affinity measurements (SPR/ELISA) for FcRn and Protein A\",\n      \"journal\": \"Protein science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — site-specific chemical modification with quantitative binding assays, mechanistically clear\",\n      \"pmids\": [\"19165723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Two FcRn molecules bind an IgG homodimer independently and with identical affinities at the two Fc sites (KD ~760 nM at pH 5.8 for human FcRn/human IgG1); in vivo serum half-life is influenced by both affinity and avidity of FcRn-IgG interactions.\",\n      \"method\": \"Surface plasmon resonance biosensor assays (artifact-controlled), in vivo PK in mouse and rat models\",\n      \"journal\": \"mAbs\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — rigorous SPR with artifact controls, consistent with crystallographic data, supported by in vivo PK\",\n      \"pmids\": [\"25658443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"An FcRn binding affinity threshold at neutral pH (pH 7.4) governs IgG recycling efficiency: Fc variants with acidic pH-enhanced binding but neutral-pH affinity below this threshold exhibit extended serum half-life, while those with neutral-pH affinity above the threshold show rapid clearance.\",\n      \"method\": \"Fc mutagenesis panel, SPR binding at pH 6.0 and 7.4, pharmacokinetic studies in human FcRn transgenic mice and cynomolgus monkeys\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with pH-dependent binding assays and in vivo PK validation in two species\",\n      \"pmids\": [\"25538249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Hepatic FcRn mediates basal recycling and bidirectional transcytosis of albumin and directs newly synthesized albumin into the basal (blood-side) milieu; liver-specific or global FcRn deletion causes hypoalbuminemia, biliary albumin loss, and intracellular albumin accumulation, and paradoxically protects from APAP-induced liver injury by increased intracellular albumin scavenging of reactive oxygen species.\",\n      \"method\": \"Global and liver-specific FcRn-knockout mice, in vitro polarized cell models, pharmacological FcRn blockade with mAbs and peptide mimetics, biochemical fractionation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — tissue-specific KO plus in vitro mechanistic models plus pharmacological intervention, multiple orthogonal readouts\",\n      \"pmids\": [\"28330995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FcRn-driven endosomal sorting directs albumin away from lysosomes: albumin with high FcRn-binding affinity is preferentially sorted to recycling (not lysosomal) compartments, with ~3.3-fold more recycled back to the medium compared to wild-type albumin, demonstrating the FcRn-dependent endosomal salvage pathway for albumin.\",\n      \"method\": \"Flow cytometry, quantitative confocal microscopy, albumin-recycling assay using wild-type and engineered albumins with varied FcRn affinities in low- and high-FcRn-expressing endothelial cell lines\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with affinity-engineered variants and multiple orthogonal cellular assays\",\n      \"pmids\": [\"28637874\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FcRn rescues albumin and IgG from degradation by mediating their rapid recycling from early macropinosomes via SNX5-positive membrane domains and tubular carriers to the plasma membrane in primary macrophages; IgG endocytosed by macropinocytosis follows this pathway, distinct from IgG bound to surface FcγRs.\",\n      \"method\": \"Primary mouse macrophages selectively expressing human FcRn, live-cell imaging, confocal microscopy, fluorescent albumin/IgG tracking, SNX5/Rab11 marker co-localization\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — primary cell model with human FcRn, multiple imaging methods, clear mechanistic distinction between pathways\",\n      \"pmids\": [\"31444284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The albumin fusion protein rIX-FP is recycled by FcRn via the albumin moiety: following internalization at low pH, rIX-FP traffics into Rab11+ recycling endosomes (within 10–15 min) and is exported from the cell; an FcRn interaction-defective albumin variant localizes to lysosomes instead.\",\n      \"method\": \"Confocal microscopy, Rab11/EEA1 co-localization, FcRn-positive vs. negative cell lines, albumin variants with FcRn-defective mutations\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection with FcRn-defective variant controls and organelle markers in relevant cell lines\",\n      \"pmids\": [\"29523681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Complementarity-determining regions (CDRs) of IgG variable domains, particularly CDR-L3, significantly alter IgG affinity for FcRn (up to 79-fold variation) and correlate with in vivo IgG clearance in human FcRn transgenic mice, beyond the canonical Fc CH2-CH3 binding interface.\",\n      \"method\": \"SPR steady-state binding assay of >50 IgG molecules with identical Fc domains but different variable regions, in vivo PK in hFcRn transgenic mice\",\n      \"journal\": \"mAbs\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — large panel SPR with in vivo PK correlation, mechanistically establishing CDR contribution to FcRn binding\",\n      \"pmids\": [\"28991504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Human cytomegalovirus US11 protein inhibits FcRn assembly with β2-microglobulin, retains FcRn in the ER, and recruits ubiquitin enzymes Derlin-1, TMEM129, and UbE2J2 to initiate ER-associated degradation (ERAD) of FcRn, thereby blocking FcRn trafficking to endosomes and reducing IgG transcytosis and IgG half-life.\",\n      \"method\": \"Co-immunoprecipitation, Western blot, IgG transcytosis assays in FcRn-expressing intestinal/placental epithelial and endothelial cells, HCMV infection experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic co-IP identifying specific ERAD machinery components, functional transcytosis assays\",\n      \"pmids\": [\"31289263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Endogenous FcRn is distributed predominantly throughout the endosomal system at steady state, with only a low percentage at the plasma membrane; a fraction of cell-surface FcRn is endocytosis-resistant while the remainder undergoes rapid endocytosis and is replenished from an internal pool.\",\n      \"method\": \"Live-cell imaging, antibody feeding assays, FACS, fluorescence microscopy of cells expressing endogenous FcRn\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiments with functional modeling, single lab\",\n      \"pmids\": [\"28817705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"FcRn-expressing MDCK cells show that FcRn and pIgR traffic through partly overlapping endosomal compartments (EEA1+, Rab11+, transferrin-positive recycling endosomes) but with directional differences; FcRn-mediated apical-to-basolateral IgG transcytosis depends on microtubules similarly to pIgR-mediated basolateral-to-apical transport.\",\n      \"method\": \"Confocal fluorescence microscopy, pulse-chase in co-transfected MDCK cells, live-cell imaging, microtubule depolymerization\",\n      \"journal\": \"Traffic\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — comparative mechanistic study in well-established model, single lab\",\n      \"pmids\": [\"20525015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FcRn mediates transplacental transport of IgE in the form of IgG anti-IgE/IgE immune complexes (but not monomeric IgE); IgG anti-IgE/IgE complexes bind to and are transcytosed by FcRn-expressing MDCK cells in an FcRn-dependent manner.\",\n      \"method\": \"FcRn-transfected MDCK cell transcytosis assays, clinical correlation of maternal/cord blood IgG anti-IgE/IgE IC levels\",\n      \"journal\": \"Clinical and experimental allergy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell-based transcytosis assay with FcRn-expressing model cells plus clinical correlation\",\n      \"pmids\": [\"25652137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The Fab region of full-length IgG impairs interaction with membrane-associated FcRn (but not soluble FcRn in cell-free assays), reducing intracellular FcRn occupancy compared to Fc-only fragments; the crystal structure of Fc-MST-HN/FcRn provides a structural explanation for why the Fab disrupts binding in the membrane context.\",\n      \"method\": \"Crystal structure determination of Fc-MST-HN/FcRn complex, cell-based FcRn binding assays, intracellular accumulation measurements, SPR (cell-free), in vivo IgG reduction in cynomolgus monkeys\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus orthogonal cell-based and in vivo assays demonstrating functional consequence\",\n      \"pmids\": [\"36241613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IgG Fab glycosylation hinders FcRn-mediated transplacental transport (~20% reduction); in a cell membrane context (but not in cell-free SPR assays) Fab glycans negatively impact IgG-FcRn interaction and reduce transcytosis efficiency.\",\n      \"method\": \"SPR, FcRn affinity chromatography (cell-free), cell membrane-context binding assays, clinical measurement of placental transfer of Fab-glycosylated IgG\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vitro methods plus in vivo clinical correlation, mechanistic distinction between cell-free and membrane-context\",\n      \"pmids\": [\"36480251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The mouse Fcgrt 5' proximal promoter contains at least two upstream regulatory regions with repressor/activator functions; transcription factors NF1, Sp1 (GT box), and Ets bind regulatory motifs; Sp1 binding to the GT box up-regulates promoter activity, while Ets binding represses it; NF1 binding differs between neonatal enterocytes and adult cells, suggesting tissue/developmental regulation of FcRn expression.\",\n      \"method\": \"Reporter gene (luciferase) assays, electrophoretic mobility shift assay (EMSA), site-directed mutagenesis of promoter elements\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — EMSA and mutagenesis establish transcription factor binding and functional effects on promoter, single lab\",\n      \"pmids\": [\"15627500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MicroRNA hsa-miR-3181 directly binds the 3'-UTR of FCGRT and reduces FCGRT mRNA and FcRn protein expression in multiple human cell lines (A549, HEK293, HepG2), identifying it as an epigenetic regulator of FcRn.\",\n      \"method\": \"Luciferase reporter assay with FCGRT 3'-UTR, microRNA mimic/inhibitor transfection, RT-qPCR, Western blot\",\n      \"journal\": \"Pharmaceutical research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — luciferase reporter with 3'-UTR plus mRNA and protein readouts, single lab\",\n      \"pmids\": [\"29302759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DNA methylation in the FCGRT regulatory region (−1058 to −587 bp) contributes to variable FcRn expression; CpG site methylation reduces binding of methylation-sensitive transcription factors Zbtb7a and Sp1, shown by chromatin immunoprecipitation in model cell lines.\",\n      \"method\": \"Quantitative DNA methylation analysis, luciferase reporter assays, chromatin immunoprecipitation (ChIP), RT-qPCR, human liver/myocardium tissue samples\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus luciferase reporter plus methylation correlation in human tissue, single lab\",\n      \"pmids\": [\"31209240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TGEV infection of porcine intestinal epithelial cells (IPEC-J2) up-regulates FcRn expression via activation of NF-κB signaling; four NF-κB binding sites in the pFcRn promoter were functionally validated by luciferase reporter, ChIP, EMSA, and supershift assays; NF-κB inhibition with BAY 11-7082 reversed this up-regulation.\",\n      \"method\": \"Luciferase reporter assay, ChIP, EMSA, supershift assay, NF-κB inhibitor (BAY 11-7082), RT-qPCR in IPEC-J2 cells\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple mechanistic methods (ChIP, EMSA, luciferase) for NF-κB regulation of pFcRn, single lab\",\n      \"pmids\": [\"27555521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Nipocalimab (anti-FcRn antibody) binds a unique epitope on the IgG-binding site of FcRn with pH-independent high affinity; its crystal structure (Fab/FcRn complex) reveals the structural basis for pH-independent binding, distinguishing it mechanistically from other FcRn antagonists; it selectively reduces IgG without affecting other immunoglobulin classes or immune functions.\",\n      \"method\": \"Crystal structure of nipocalimab Fab/FcRn complex, cell-based FcRn occupancy assays, in vivo dose-response studies in mice and cynomolgus monkeys\",\n      \"journal\": \"mAbs\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with cell-based and in vivo functional validation\",\n      \"pmids\": [\"39936406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Different FcRn antagonists differentially affect albumin homeostasis through two mechanisms: (1) increased degradation of FcRn itself (reducing overall FcRn-mediated recycling of albumin) and (2) direct competition between the antagonist and albumin for FcRn binding, with the relative contribution of each mechanism varying by antagonist.\",\n      \"method\": \"Cellular and molecular analyses of a panel of FcRn antagonists, FcRn degradation assays, competitive binding assays\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic cellular analyses with panel comparison, single lab\",\n      \"pmids\": [\"38713534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FcRn-dependent IgG recycling in adipose progenitor cells and macrophages governs IgG accumulation in adipose tissue during obesity; this accumulated IgG interacts with the insulin receptor ectodomain via its Fc-CH3 domain, hindering insulin binding and impairing insulin signaling; targeting FcRn abolished IgG accumulation and corrected insulin resistance in diet-induced obesity.\",\n      \"method\": \"Diet-induced obesity mouse models, FcRn targeting in vivo, AI-assisted modeling of IgG/insulin receptor interaction, in vitro insulin signaling assays, macrophage/progenitor cell analyses\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo FcRn targeting with defined metabolic phenotype plus molecular interaction modeling, single lab, some mechanistic steps computational\",\n      \"pmids\": [\"39674176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"FcRn is expressed in normal human epidermal keratinocytes, localized in cytoplasmic vesicular/granular structures predominantly intracellularly, and binds human IgG in an Fc-dependent, pH-dependent manner (at acidic pH).\",\n      \"method\": \"RT-PCR, Northern blot, immunoblot, immunoprecipitation, immunofluorescence microscopy, FACS, IgG binding assay at acidic pH\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods establishing FcRn expression and functional IgG binding in keratinocytes, single lab\",\n      \"pmids\": [\"15654966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"FcRn is expressed on human intestinal epithelial cells (fetal and adult), localized predominantly in the apical region of enterocytes, consistent with its role in IgG binding and transport.\",\n      \"method\": \"RT-PCR, Western blot, immunohistochemistry of human fetal and adult intestinal tissue\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — localization established by immunohistochemistry and Western blot, single lab, no direct functional assay\",\n      \"pmids\": [\"9370926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Human FcRn expression is required for Echovirus 11 (E11) pathogenesis in mice; hFcRn serves as the primary receptor for echoviruses, but hFcRn expression alone is insufficient for susceptibility—ablation of type I IFN signaling in addition to hFcRn expression recapitulates echovirus pathogenesis and liver damage observed in humans.\",\n      \"method\": \"hFcRn transgenic mice, IFNAR-knockout mice, in vivo echovirus infection, Luminex multianalyte profiling, histopathology\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in transgenic/KO mice with clear in vivo phenotype, single lab\",\n      \"pmids\": [\"33513208\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FcRn (encoded by FCGRT) is an MHC class I-related heterodimer (α-chain/β2-microglobulin) that binds IgG and albumin in a pH-dependent manner (tight at acidic endosomal pH ~6, negligible at physiological pH ~7.4) within intracellular vesicles of diverse cell types—including endothelial cells, epithelial cells, neutrophils, macrophages, hepatocytes, and keratinocytes—where it salvages both ligands from lysosomal degradation by routing them through Rab11+ recycling endosomes/SNX5+ macropinosome tubules back to the cell surface, thereby maintaining long serum half-lives of IgG and albumin; additionally, FcRn mediates bidirectional transcytosis of IgG across polarized epithelia (intestine, placenta, nasal, BBB), facilitates phagocytosis of IgG-opsonized bacteria in a pH-dependent manner in neutrophils, delivers IgG immune complexes to antigen-presentation compartments, and can be exploited or blocked therapeutically to either extend IgG half-life (via Fc engineering) or accelerate IgG catabolism (via FcRn antagonists) for treating autoimmune diseases.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"FcRn (encoded by FCGRT) is an MHC class I-related α-chain that heterodimerizes with β2-microglobulin and functions as the principal pH-dependent receptor for IgG and albumin homeostasis, mucosal immunity, and transplacental IgG transfer. FcRn binds IgG at the CH2–CH3 domain interface and albumin at acidic endosomal pH (~6.0) while releasing both ligands at neutral pH (~7.4), thereby diverting them from lysosomal degradation into Rab11-positive recycling endosomes and SNX5-positive tubular carriers for return to the cell surface [PMID:14764666, PMID:11847107, PMID:31444284, PMID:28637874]. In polarized epithelia and endothelia—including intestinal, placental, and endothelial cells—FcRn additionally mediates bidirectional transcytosis of IgG, with transcytosis directionality regulated by ligand-induced receptor redistribution and dependent on microtubules and PI3-kinase signaling [PMID:10510331, PMID:11182218, PMID:20525015]. Beyond IgG/albumin salvage, FcRn enhances neutrophil phagocytosis of IgG-opsonized bacteria in a pH-dependent manner, serves as a primary receptor for echovirus entry, and its hepatic expression directs polarized albumin secretion and recycling; FcRn is subject to transcriptional regulation by NF-κB, Sp1, Zbtb7a, and post-transcriptional regulation by miR-3181, and is targeted for ER-associated degradation by the HCMV immune evasin US11 [PMID:16849638, PMID:33513208, PMID:28330995, PMID:31209240, PMID:29302759, PMID:31289263].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing that FcRn is expressed in human adult and fetal intestinal epithelium resolved the question of whether the neonatal Fc receptor, initially studied in rodents, also operates in human gut, opening the field to studying its mucosal immune function in humans.\",\n      \"evidence\": \"RT-PCR, Western blot, and immunohistochemistry of human fetal and adult intestinal tissue\",\n      \"pmids\": [\"9370926\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct functional transport assay performed\", \"Expression levels across intestinal segments not quantified\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrating that FcRn is expressed in endothelial cells within intracellular vesicles established that vascular endothelium—not just epithelium—is the principal site of IgG homeostatic regulation in the adult.\",\n      \"evidence\": \"Immunohistochemistry, immunoprecipitation, and immunofluorescence of murine endothelial cells\",\n      \"pmids\": [\"9786428\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human endothelial expression not directly shown in this study\", \"Mechanism of IgG sorting not yet addressed\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Showing that FcRn mediates bidirectional, pH-dependent IgG transcytosis across polarized human intestinal epithelial cells established FcRn as a mucosal IgG transport receptor in humans, not merely a salvage receptor.\",\n      \"evidence\": \"Transcytosis assays in polarized T84 monolayers with endosomal acidification inhibition\",\n      \"pmids\": [\"10510331\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo confirmation of bidirectional transport in human intestine not yet available\", \"Relative contribution of apical-to-basolateral vs. basolateral-to-apical flux not quantified in vivo\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Mapping the FcRn binding site to the IgG1 Fc CH2–CH3 domain interface via systematic alanine-scanning mutagenesis defined the molecular footprint governing FcRn-IgG interaction and enabled rational Fc engineering.\",\n      \"evidence\": \"Alanine-scanning mutagenesis of IgG1 Fc with SPR and ELISA binding assays for FcRn and other FcγRs\",\n      \"pmids\": [\"11096108\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full structural model of the human FcRn–IgG complex not yet available at this time\", \"Contribution of IgG variable regions not addressed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Reconstitution in polarized MDCK cells revealed that FcRn-mediated transcytosis involves ligand-induced receptor redistribution and routing through Rab11-positive recycling endosomes, with basolateral recycling dependent on PI3-kinase, establishing the intracellular trafficking itinerary of FcRn.\",\n      \"evidence\": \"Pulse-chase, confocal microscopy, and wortmannin inhibition in polarized MDCK cells expressing rat FcRn\",\n      \"pmids\": [\"11847107\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human FcRn trafficking may differ from rat FcRn in this heterologous system\", \"Identity of adaptor proteins linking FcRn to sorting machinery unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Live-cell imaging in human endothelial cells demonstrated that FcRn sorts IgG away from multivesicular bodies destined for lysosomes and into recycling tubules, providing direct visualization of the IgG salvage mechanism.\",\n      \"evidence\": \"Live-cell imaging of FcRn-GFP in human endothelial cells with fluorescent IgG tracking\",\n      \"pmids\": [\"14764666\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular determinants of FcRn exit from sorting endosomes not identified\", \"Quantitative stoichiometry of salvage vs. degradation not measured\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identification of Sp1, NF1, and Ets binding sites in the Fcgrt promoter with opposing regulatory activities established that FcRn expression is actively controlled at the transcriptional level with tissue- and developmental-stage-specific modulation.\",\n      \"evidence\": \"Luciferase reporter assays, EMSA, and site-directed mutagenesis of the mouse Fcgrt promoter\",\n      \"pmids\": [\"15627500\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mouse promoter elements may not fully recapitulate human FCGRT regulation\", \"In vivo relevance of each transcription factor binding site not confirmed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Two discoveries broadened FcRn biology beyond recycling: FcRn expression in neutrophil granules with relocation to phagolysosomes established a role in innate immunity via enhanced phagocytosis, while the YTE Fc mutation demonstrated that engineered FcRn affinity enhancement extends IgG half-life in primates, validating FcRn as a therapeutic target.\",\n      \"evidence\": \"FcRn-KO and β2M-KO neutrophil phagocytosis assays with IgG-opsonized bacteria; Fc-YTE mutagenesis with in vitro binding and in vivo PK in cynomolgus monkeys\",\n      \"pmids\": [\"16849638\", \"16793771\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which FcRn enhances phagocytosis in the acidic phagolysosome not fully defined\", \"Long-term immunological consequences of YTE-mediated extended half-life not assessed\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showing that oxidation of Met252 and Met428 at the Fc–FcRn interface reduces FcRn binding established that post-translational modifications of IgG can modulate FcRn-dependent serum persistence.\",\n      \"evidence\": \"In vitro methionine oxidation of IgG2 Fc followed by SPR/ELISA binding to FcRn and Protein A\",\n      \"pmids\": [\"19165723\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo significance of methionine oxidation on IgG half-life not directly tested\", \"Whether FcRn itself undergoes oxidative modifications affecting function is unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Quantitative SPR demonstrated that two FcRn molecules bind independently to both Fc sites of an IgG homodimer with identical affinity (~760 nM at pH 5.8), and that a neutral-pH affinity threshold governs whether enhanced acidic-pH binding translates to extended or shortened half-life, establishing the biophysical rules for Fc half-life engineering.\",\n      \"evidence\": \"Artifact-controlled SPR with stoichiometric analysis; Fc mutagenesis panel with PK in hFcRn transgenic mice and cynomolgus monkeys\",\n      \"pmids\": [\"25658443\", \"25538249\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How avidity at the membrane surface modifies these solution-phase affinity rules is not fully resolved\", \"The pH 7.4 threshold value may differ for non-IgG1 subclasses\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Three studies converged to establish FcRn as a dual IgG/albumin homeostatic receptor: liver-specific FcRn deletion caused hypoalbuminemia and biliary albumin loss; FcRn-dependent endosomal sorting diverted albumin from lysosomes to recycling compartments with affinity-tunable efficiency; and IgG variable-domain CDRs were shown to modulate FcRn binding up to 79-fold beyond canonical Fc determinants.\",\n      \"evidence\": \"Liver-specific FcRn-KO mice with pharmacological blockade; albumin recycling assays with affinity-engineered variants in endothelial cells; SPR panel of >50 IgGs with identical Fc domains and PK in hFcRn transgenic mice\",\n      \"pmids\": [\"28330995\", \"28637874\", \"28991504\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for CDR-mediated modulation of FcRn binding not determined\", \"Relative contribution of hepatic vs. endothelial FcRn to systemic albumin homeostasis not quantified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Tracking albumin fusion proteins through Rab11+ recycling endosomes confirmed the FcRn-dependent endosomal salvage route operates for albumin-conjugated therapeutics, while miR-3181 was identified as a post-transcriptional repressor of FCGRT expression.\",\n      \"evidence\": \"Confocal microscopy with Rab11/EEA1 markers and FcRn-defective albumin variants; luciferase 3′-UTR reporter assay with miR-3181 mimic/inhibitor in multiple cell lines\",\n      \"pmids\": [\"29523681\", \"29302759\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of miR-3181 regulation of FcRn not demonstrated\", \"Whether other miRNAs coordinately regulate FCGRT is unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Three findings expanded FcRn biology: in macrophages, FcRn rescues IgG and albumin via SNX5-positive macropinosome tubules distinct from FcγR-mediated uptake; HCMV US11 protein targets FcRn for ER-associated degradation via Derlin-1/TMEM129/UbE2J2 to evade antibody-mediated immunity; and DNA methylation of CpG sites in the FCGRT promoter modulates Zbtb7a/Sp1 binding and FcRn expression levels.\",\n      \"evidence\": \"Live-cell imaging in primary macrophages with SNX5/Rab11 markers; co-IP identifying ERAD components with transcytosis assays during HCMV infection; ChIP, luciferase reporters, and methylation analysis in cell lines and human tissues\",\n      \"pmids\": [\"31444284\", \"31289263\", \"31209240\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other herpesviruses employ analogous FcRn evasion strategies is unknown\", \"Functional significance of SNX5 vs. Rab11 route selectivity not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrating that human FcRn serves as the primary entry receptor for Echovirus 11 in transgenic mice—with pathogenesis requiring concomitant loss of type I IFN signaling—established FcRn as a dual-use receptor exploited by enteroviruses.\",\n      \"evidence\": \"hFcRn transgenic and IFNAR-KO mice infected with echovirus, with Luminex profiling and histopathology\",\n      \"pmids\": [\"33513208\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of echovirus–FcRn interaction not resolved\", \"Whether FcRn-mediated transcytosis facilitates viral dissemination not directly tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Crystal structure of an engineered Fc/FcRn complex revealed that the IgG Fab domain sterically impairs FcRn interaction in a membrane context, explaining why Fc-only fragments occupy FcRn more efficiently than full-length IgG—informing FcRn antagonist design.\",\n      \"evidence\": \"X-ray crystallography of Fc-MST-HN/FcRn complex with cell-based FcRn occupancy assays and in vivo IgG reduction in cynomolgus monkeys\",\n      \"pmids\": [\"36241613\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length IgG/FcRn co-structure on membrane not yet available\", \"How Fab glycosylation synergizes with steric hindrance mechanistically is unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Two studies connected FcRn to metabolic disease and therapeutic mechanism: FcRn-dependent IgG recycling in adipose progenitor cells and macrophages drives obesity-associated IgG accumulation that impairs insulin receptor signaling, while different FcRn antagonists were shown to reduce albumin levels through distinct mechanisms—FcRn degradation versus direct competition for albumin binding.\",\n      \"evidence\": \"Diet-induced obesity mouse models with FcRn targeting and insulin signaling assays; cellular panel comparison of FcRn antagonists with degradation and competitive binding assays\",\n      \"pmids\": [\"39674176\", \"38713534\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"AI-assisted modeling of IgG–insulin receptor interaction awaits experimental structural validation\", \"Clinical translation of FcRn targeting for insulin resistance not tested\", \"Relative importance of FcRn degradation vs. competition for albumin binding in patients not determined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"The crystal structure of nipocalimab Fab bound to FcRn defined a unique pH-independent epitope on the IgG-binding site, explaining how this antagonist selectively blocks IgG recycling without affecting other immunoglobulin classes, providing a structural framework for selective FcRn antagonism.\",\n      \"evidence\": \"Crystal structure of nipocalimab Fab/FcRn complex with cell-based FcRn occupancy and in vivo dose-response in mice and monkeys\",\n      \"pmids\": [\"39936406\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term effects of sustained pH-independent FcRn blockade on albumin levels not fully characterized\", \"Whether epitope differences among FcRn antagonists produce distinct clinical efficacy profiles is unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of simultaneous IgG and albumin co-binding and sorting on the same FcRn molecule, the identity of adaptor proteins linking FcRn cytoplasmic tail to endosomal sorting machinery, and the quantitative contribution of FcRn in specific tissues (e.g., liver vs. endothelium vs. hematopoietic cells) to systemic IgG and albumin homeostasis.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full-length IgG/albumin/FcRn co-structure on membranes\", \"Adaptor proteins for FcRn cytoplasmic tail sorting signals not identified\", \"Tissue-specific conditional knockout studies with quantitative PK modeling incomplete\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [0, 2, 7, 12, 14]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 6, 7, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [1, 2, 7, 13, 17]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [1, 2, 14, 29]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [17]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [0, 2, 6, 7, 11, 13, 14]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 19, 31]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [2, 12, 16]}\n    ],\n    \"complexes\": [\n      \"FcRn–β2-microglobulin heterodimer\"\n    ],\n    \"partners\": [\n      \"B2M\",\n      \"SNX5\",\n      \"RAB11\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}